TY - JOUR T1 - Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02202-2022 VL - 61 IS - 3 SP - 2202202 AU - Jonathan Corren AU - Christopher E. Brightling AU - Louis-Philippe Boulet AU - Celeste Porsbjerg AU - Michael E. Wechsler AU - Andrew Menzies-Gow AU - Christopher S. Ambrose AU - Bill Cook AU - Neil Martin AU - Joseph Spahn AU - Jean-Pierre Llanos Y1 - 2023/03/01 UR - http://erj.ersjournals.com/content/61/3/2202202.abstract N2 - Tezepelumab, a biologic therapy for severe asthma, blocks TSLP activity, subsequently downregulating multiple type 2 inflammatory pathways and reducing airway hyperresponsiveness via eosinophil-independent effects https://bit.ly/3XGpaV3Tezepelumab is a human monoclonal antibody (IgG2λ) approved in several countries and regions, including the USA and the EU, for the treatment of severe asthma. Approval was based on evidence from the phase 2b PATHWAY study (NCT02054130) and the phase 3 NAVIGATOR study (NCT03347279) [1, 2]. Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cytokine. Questions have been raised about the mechanisms of action of tezepelumab in patients with asthma, particularly regarding the effects beyond reductions in eosinophil counts in the blood and airways [3]. Here, we outline clinical evidence and mechanistic insights from randomised clinical trials supporting the multiple mechanisms of tezepelumab, including those relevant to type 2 (T2)-high and T2-low asthma.Medical writing support was provided by Priyanka Narang of PharmaGenesis London, London, UK, with funding from AstraZeneca and Amgen Inc. Andrew Menzies-Gow has a new and additional affiliation of Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK. ER -